# JAVELIN Bladder 100

Source: https://onco.cc/trials/javelin-bladder-100/  
OnCo record `javelin-bladder-100` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Starting immunotherapy right after chemotherapy, rather than waiting for relapse, lengthened survival by about seven months.

## Summary

JAVELIN Bladder 100, trial NCT02603432 sponsored by Merck KGaA and Pfizer and reported in 2020, showed that starting avelumab immunotherapy immediately after platinum chemotherapy, rather than waiting for relapse, lengthened survival in advanced urothelial cancer. It randomised 700 patients without progression after four to six cycles of platinum chemotherapy to avelumab maintenance with best supportive care or supportive care alone and met its primary overall survival endpoint, making avelumab maintenance the standard after platinum for four years. OnCo links it to bladder cancer, avelumab and Thomas Powles. It was superseded rather than contradicted when EV-302 displaced platinum from first-line treatment for most patients, and it remains relevant where enfortumab vedotin plus pembrolizumab is unavailable or contraindicated.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT02603432
- Phase: 3
- Setting: Advanced urothelial cancer without progression after 4-6 cycles of platinum chemotherapy: avelumab maintenance + best supportive care vs BSC
- Sponsor: Merck KGaA / Pfizer
- Enrolled: 700
- Result: OS 21.4 vs 14.3 months, HR 0.69.
- Outcomes: Overall survival: Avelumab + BSC 21.4 months vs BSC 14.3 months, HR 0.69
- Replication: Consistent with real-world maintenance series; superseded rather than contradicted by EV-302.

## Sources

- ClinicalTrials.gov NCT02603432: https://clinicaltrials.gov/study/NCT02603432

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- people: [Thomas Powles](https://onco.cc/people/thomas-powles/)
- key papers: [JAVELIN Bladder 100: avelumab maintenance after first-line platinum chemotherapy in advanced urothelial cancer](https://onco.cc/key-papers/paper-javelin-bladder-100-nejm-2020/)

---
JSON: https://onco.cc/api/v1/entities/javelin-bladder-100.json